Spectrum gaps down sharply, levels to watch The shares are one of the biggest losers in markets today after the company cut guidance for its fiscal year 2013 revenues to a range of $160 to $180 million versus consensus of $297 million. At the current price of $7.83, putting the shares down 37%, the next support is at $7.52. Resistance is at $8.13.
News For SPPI From The Last 14 Days
Check below for free stories on SPPI the last two weeks.
Spectrum reports Q1 EPS (5c), consensus (16c) Reports Q1 revenue $38.7M, consensus $36.42M. Says pivotal data in relapsed/refractory peripheral T-cell lymphoma from late-stage drug Belinostat to be presented as an oral presentation at ASCO 2013; the company expects to submit an NDA this summer. Company expects enrollment in the Captisol-enabled melphalan study in multiple myeloma to be completed in 2013, with NDA submission in 2014.